ReviewCurrent opinion in HIV and AIDS2010
Strategies for eliciting HIV-1 inhibitory antibodies.
Review in Current opinion in HIV and AIDS, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Trial
- The importance of semen leukocytes in HIV-1 transmission and the development of prevention strategies.Human vaccines & immunotherapeutics · 2020Review
- Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection.Frontiers in microbiology · 2018Article
- Mathematical model of multivalent virus-antibody complex formation in humans following acute and chronic HIV infections.Journal of mathematical biology · 2015Article
- Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.PLoS pathogens · 2015Article
- Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.Journal of virology · 2014Observational
- Aggregate complexes of HIV-1 induced by multimeric antibodies.Retrovirology · 2014Article
- Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity.Journal of virology · 2014Article
- HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life.Mucosal immunology · 2013Article
- Designing tomorrow's vaccines.The New England journal of medicine · 2013Review
- Understanding and learning from the success of prophylactic human papillomavirus vaccines.Nature reviews. Microbiology · 2012Review
- Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.Vaccine · 2012Article
- HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.Journal of virology · 2012Article
- The design and evaluation of HIV-1 vaccines.AIDS (London, England) · 2012Review
- Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.Virology · 2012Article
- Article
- Role of IL-21 and IL-21 receptor on B cells in HIV infection.Critical reviews in immunology · 2012Review
- Influence of dendritic cells on B-cell responses during HIV infection.Clinical & developmental immunology · 2012Review
- Article
- Natural Immunity to HIV: a delicate balance between strength and control.Clinical & developmental immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewMajor roadblocks persist in the development of vaccines that elicit potent neutralizing antibodies targeting diverse HIV-1 strains, similar to known broadly neutralizing HIV-1 human monoclonal antibodies. Alternatively, other types of anti-HIV-1 envelope antibodies that may not neutralize HIV-1 in traditional neutralization assays but have other anti-HIV-1 activities (hereafter termed HIV-1 inhibitory antibodies) can be elicited by current vaccine strategies, and numerous studies are exploring their roles in preventing HIV-1 acquisition. We review examples of strategies for eliciting potentially protective HIV-1 inhibitory antibodies. RECENT
findingsHeterologous prime-boost strategies can yield anti-HIV immune responses, although only one (canarypox prime, Env protein boost) has been tested and shown positive results in an efficacy trial (RV144). Although the immune correlates of protection are as yet undefined, the reduced rate of acquisition without a significant effect on initial viral loads or CD4 T-cell counts, have raised the hypothesis of an RV144 vaccine-elicited transient protective B-cell response. SUMMARY: In light of the RV144 trial, there is a critical need to define the entire functional spectrum of anti-HIV-1 antibodies, how easily each can be elicited, and how effective different types of antibody effector mechanisms can be in prevention of HIV-1 transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.